Medical device company Bigfoot Biomedical Inc disclosed on Monday that secured USD45m from the initial tranche of a Series C equity financing.
The round is led by Abbott with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, as well as Cormorant Asset Management.
Proceeds will be used to support the completion of product development and FDA clearance for the Bigfoot Unity Diabetes Management Programme, an injection-based digitized insulin dosing platform utilizing a proprietary, connected insulin pen-based system that integrates Abbott's FreeStyle Libre glucose sensing technology. Submission is anticipated in 2020 with a target launch by year-end 2020.
In addition, the Series C funds will be directed toward clinical trials of future generation Bigfoot Unity systems incorporating closed-loop technology for injection users.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid